

# for POLIVY® (polatuzumab vedotin-piiq)

## SAMPLE CODING

### Diffuse Large B-cell Lymphoma

TYPE	CODE	DESCRIPTION
Diagnosis: ICD-10-CM	C83.30	Diffuse large B-cell lymphoma, unspecified site
	C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck
	C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes
	C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes
	C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb
	C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb
	C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes
	C83.37	Diffuse large B-cell lymphoma, spleen
	C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites
	C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites
Drug: HCPCS	J9309	Injection, polatuzumab vedotin-piiq, 1 mg
HCPCS: Modifier* Note: Beginning July 1, 2023, CMS requires the use of the JZ modifier to indicate there were no units of a drug discarded.	JW	Drug amount discarded/not administered to any patient
	JZ	Zero drug amount discarded/not administered to any patient

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

\*The JW modifier is required on claims for all single-dose containers or single-use drugs when an amount is discarded. While not required until July 1, 2023, the JZ modifier is available for use as of January 1, 2023. For more information on the JW and JZ modifiers, visit CMS.gov.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

for **POLIVY®**

(polatuzumab vedotin-piiq)

Diffuse Large B-cell Lymphoma (cont)

TYPE	CODE		DESCRIPTION
<b>Drug: NDC</b>  <b>Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.</b>	10-digit	11-digit	
	50242-103-01	50242-0103-01	30-mg single-dose vial
	50242-105-01	50242-0105-01	140-mg single-dose vial
<b>Administration procedures: CPT</b>	96413		Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415		Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)
	96417		Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)

CMS=Centers for Medicare & Medicaid Services; CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; NDC=National Drug Code.

**These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any item or service.**

**Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.**